Cat. No.: DAB-0012780
Product Information | |
---|---|
Clonality | Monoclonal |
Host Species | Rabbit |
Product Description | Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ala71 of human LAMTOR1/C11orf59 protein, residues surrounding Leu31 of human LAMTOR2/ROBLD3 protein, residues surrounding Val16 of human LAMTOR3/MAPKSP1 protein, a synthetic peptide corresponding to the sequence of human RagA protein or residues in the amino terminus of human RagB, and RagC protein. Polyclonal antibody is produced by immunizing animal with a synthetic peptide corresponding to the sequence of human RagD proteins. Polyclonal antibodies are purified by protein A and peptide affinity chromatography. |
Format | Liquid |
Purity | Affinity purity |
Target Information | |
---|---|
Gene Description | The mTORC kinase complex is a critical regulator of cell growth. Its activity is modulated by energy levels, growth factors, and amino acids via signaling through Akt, MAPK, and AMPK pathways. Recent studies found that the four related GTPases, RagA, RagB, RagC, and RagD, interact with raptor within the mTORC1 complex. These interactions are both necessary and sufficient for mTORC1 activation in response to amino acid signals. According to the research literature, RagD is one of several genes differentially expressed in human melanoma cell lines and has been considered to be a viable target for further diagnostic and therapeutic study. A protein complex consisting of LAMTOR1/C11orf59, LAMTOR2/ROBLD3, and LAMTOR3/MAPKSP1 has been identified to interact with and recruit four Rag GTPases to the surface of lysosomes. |
Shipping & Storage | |
---|---|
Shipping | Shipped at 4 °C. |
Storage Instructions | Store at +4 °C short term (1-2 weeks). Store at -20 °C long term. |
Storage Buffer | Constituent: 100% PBS |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.